NCT02363621View on ClinicalTrials.gov

Evaluation of Inflammation and Pain Post Injection of Ranibizumab vs Aflibercept in Patients With DME

PHASE2CompletedINTERVENTIONAL
Enrollment

101

Participants

Timeline

Start Date

January 31, 2015

Primary Completion Date

October 31, 2017

Study Completion Date

October 31, 2017

Conditions
Diabetic Macular Edema
Interventions
DRUG

Ranibizumab 0.3 mg

Ranibizumab 0.3 mg Patient will receive intravitreal injection of Ranibizumab 0.3 mg

DRUG

Aflibercept 2.0 mg

Patient will receive intravitreal injection of Aflibercept 2.0 mg

Trial Locations (1)

89502

Sierra Eye Associates, Reno

Sponsors

Collaborators (1)

Genentech, Inc.
All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

lead

Arshad Khanani

OTHER